Jeremy L. Johnson, PharmD, BCACP, CDCES, BC-ADM

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Older triglyceride drugs manage only 10% to 30% reductions; newer injectables go far further, with FCS as their first key role.

Jeremy Johnson, PharmD, on how oral and injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are helping high-risk patients hit LDL targets statins alone can't reach.